Airlift is about the braveheart Ranjit Katyal, the unsung unknown hero who masterminded the evacuation of thousands of Indians stranded in Kuwait in August 1990 when Saddam Hussein’s ...

It’s time to pay tribute to an absolute all time classic! The sort of film that just never gets old, regardless of how many times you've watched it, as we’re going to look at the 1995 historical epic ...

The final College Football Rankings have been released, meaning the official 12-team bracket is set. Sunday's reveal might bring ramifications to the postseason format after five-loss Duke won the ACC ...

Reaction videos are everywhere. Whether it is a YouTuber breaking down a music video, a streamer commenting on a movie trailer, or a TikTok creator responding to viral clips, audiences love watching ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s one of the largest ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

NEW YORK CITY – Curtis Sliwa says he’s charging into the final stretch of New York City’s mayoral race like "Braveheart" — confident, defiant and ready to die on his sword for the city he loves. In an ...

The Pentagon is moving forward on orders from President Donald Trump to build a National Guard quick reaction force in each state for domestic use, though two US officials say the effort is largely ...

Braveheart Bio has waded into the fight for a heart disease market, paying (PDF) $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten. Jiangsu Hengrui ...